Avid Radiopharmaceuticals to Present at the Inaugural Jefferies Global Life Sciences Conference on June 10th
PHILADELPHIA--(BUSINESS WIRE)--Jun 7, 2010 - Avid Radiopharmaceuticals, Inc., a leader in the development of products with the potential for earlier and more effective detection, diagnosis and monitoring of brain disorders, today announced that Daniel M. Skovronsky, MD, PhD, Founder and CEO of Avid, will present at the Inaugural Jefferies Global Life Sciences Conference on Thursday, June 10, 2010 at 4:30pm EDT. The conference will be held at The Grand Hyatt Hotel in New York City.
Dr. Skovronsky will provide attendees with an update on clinical trials and commercialization efforts for Avid's amyloid imaging compound florbetapir F 18 (18F-AV-45) (“florbetapir”). This tracer is the most advanced compound of its type in development for imaging amyloid plaque in the brain associated with Alzheimer's disease. In 2009, florbetapir entered a pivotal Phase III registration study.
Avid's second program, 18F-AV-133 (“AV-133”) PET imaging of the vesicular monoamine transporter 2 (VMAT2) in patients with suspected dopaminergic degeneration, is currently in Phase II clinical trials. AV-133 has also been shown to be a marker for beta cells of the pancreas in preclinical studies. The compound is now in Phase I studies to test the ability of this molecular imaging agent to distinguish type 1 and type 2 diabetes subjects from healthy normal individuals based on a PET scan of the pancreas.
About Avid Radiopharmaceuticals, Inc.
Avid Radiopharmaceuticals is a leader in the development of molecular imaging products with the potential for earlier and more effective detection, diagnosis and monitoring of major chronic human diseases. Based in Philadelphia, PA, the company's lead program is a molecular imaging agent for amyloid plaque that could lead to earlier detection and better evaluation of drugs designed to prevent or reverse amyloid plaque build-up in the brain. Avid is currently conducting Phase III clinical studies of florbetapir for imaging amyloid plaques in Alzheimer's disease, and is in Phase I and II trials with 18F-AV-133 for imaging the vesicular monoamine transporter (VMAT2) in diseases involving dopaminergic degeneration (Parkinson's disease and Dementia with Lewy Bodies) and beta cell dysfunction (Type I and Type II Diabetes Mellitus). For more information, please visit www.avidrp.com.
Contact: Avid Radiopharmaceuticals, Inc.
Richard A. Baron
Chief Financial Officer
Posted: June 2010